Francesco Bertoni
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
Spriano F, Sartori G, Sgrignani J, Barnabei L, Arribas A, Guala M, Del Amor A, Tomasso M, Tarantelli C, Cascione L, Golino G, Riveiro M, Bortolozzi R, Lupia A, Paduano F, Huguet S, Rezai K, Rinaldi A, Margheriti F, Ventura-Aguiar P, Guarda G, Costa G, Rocca R, Furlan A, Verdonk L, Innocenti P, Martin N, Viola G, Driessen C, Zucca E, Stathis A, Gahtory D, Van den Nieuwboer M, Bornhauser B, Alcaro S, Trapasso F, Cristobal S, Padrick S, Pazzi N, Cavalli F, Cavalli A, Gaudio E, Bertoni F. A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers. Haematologica 2024
20.06.2024A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
20.06.2024Haematologica 2024
Spriano Filippo, Sartori Giulio, Sgrignani Jacopo, Barnabei Laura, Arribas Alberto, Guala Matilde, Del Amor Ana Maria Carrasco, Tomasso Meagan R, Tarantelli Chiara, Cascione Luciano, Golino Gaetanina, Riveiro Maria E, Bortolozzi Roberta, Lupia Antonio, Paduano Francesco, Huguet Samuel, Rezai Keyvan, Rinaldi Andrea, Margheriti Francesco, Ventura-Aguiar Pedro, Guarda Greta, Costa Giosuè, Rocca Roberta, Furlan Alberto, Verdonk Luuk M, Innocenti Paolo, Martin Nathaniel I, Viola Giampietro, Driessen Christoph, Zucca Emanuele, Stathis Anastasios, Gahtory Digvijay, Van den Nieuwboer Maurits, Bornhauser Beat, Alcaro Stefano, Trapasso Francesco, Cristobal Susana, Padrick Shae B, Pazzi Natalina, Cavalli Franco, Cavalli Andrea, Gaudio Eugenio, Bertoni Francesco
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv 2022; 6:3911-3920.
12.07.2022SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
12.07.2022Blood Adv 2022; 6:3911-3920
Stathis Anastasios, Mey Ulrich, Schär Sämi, Hitz Felicitas, Pott Christiane, Mach Nicolas, Krasniqi Fatime, Novak Urban, Schmidt Christian, Hohloch Karin, Kienle Dirk, Hess Dagmar, Moccia Alden A, Unterhalt Michael, Eckhardt Katrin, Hayoz Stefanie, Forestieri Gabriela, Rossi Davide, Dirnhofer Stefan, Ceriani Luca, Sartori Giulio, Bertoni Francesco, Buske Christian, Zucca Emanuele, Hiddemann Wolfgang
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa M, Cittone M, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista M, Bastidas G, Beà S, Boldorini R, Broccoli A, Buehler M, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia A, Facchetti F, Gaidano G, Garcia J, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier D, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer J, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani P, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, de Leval L, Dirnhofer S, Pileri S, Piris M, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood 2022; 139:732-747.
03.02.2022Genetic and phenotypic attributes of splenic marginal zone lymphoma.
03.02.2022Blood 2022; 139:732-747
Bonfiglio Ferdinando, Bruscaggin Alessio, Guidetti Francesca, Terzi di Bergamo Lodovico, Faderl Martin Richard, Spina Valeria, Condoluci Adalgisa, Bonomini Luisella, Forestieri Gabriela, Koch Ricardo, Piffaretti Deborah, Pini Katia, Pirosa Maria Cristina, Cittone Micol Giulia, Arribas Alberto, Lucioni Marco, Ghilardi Guido, Wu Wei, Arcaini Luca, Baptista Maria Joao, Bastidas Gabriela, Beà Silvia, Boldorini Renzo, Broccoli Alessandro, Buehler Marco, Canzonieri Vincenzo, Cascione Luciano, Ceriani Luca, Cogliatti Sergio, Corradini Paolo, Derenzini Enrico, Devizzi Liliana, Dietrich Sascha, Elia Angela Rita, Facchetti Fabio, Gaidano Gianluca, Garcia Juan Fernando, Gerber Bernhard, Ghia Paolo, Gomes da Silva Maria, Gritti Giuseppe, Guidetti Anna, Hitz Felicitas, Inghirami Giorgio, Ladetto Marco, López-Guillermo Armando, Lucchini Elisa, Maiorana Antonino, Marasca Roberto, Matutes Estella, Meignin Véronique, Merli Michele, Moccia Alden, Mollejo Manuela, Montalban Carlos, Novak Urban, Oscier David Graham, Passamonti Francesco, Piazza Francesco A, Pizzolitto Stefano, Rambaldi Alessandro, Sabattini Elena, Salles Gilles Andre, Santambrogio Elisa, Scarfo Lydia, Stathis Anastasios, Stussi Georg, Geyer Julia Turbiner, Tapia Gustavo, Tarella Corrado, Thieblemont Catherine, Tousseyn Thomas, Tucci Alessandra, Vanini Giorgio, Visco Carlo, Vitolo Umberto, Walewska Renata, Zaja Francesco, Zenz Thorsten, Zinzani Pier Luigi, Khiabanian Hossein, Calcinotto Arianna, Bertoni Francesco, Bhagat Govind, Campo Elias, de Leval Laurence, Dirnhofer Stefan, Pileri Stefano A, Piris Miguel A, Traverse-Glehen Alexandra, Tzankov Alexander, Paulli Marco, Ponzoni Maurilio, Mazzucchelli Luca, Cavalli Franco, Zucca Emanuele, Rossi Davide
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Pirosa M, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, Stathis A. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leuk Lymphoma 2021; 63:117-123.
19.08.2021A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
19.08.2021Leuk Lymphoma 2021; 63:117-123
Pirosa Maria C, Zhang Lu, Hitz Felicitas, Novak Urban, Hess Dagmar, Terrot Tatiana, Pascale Mariarosa, Mazzucchelli Luca, Bertoni Francesco, Cavalli Franco, Zucca Emanuele, Stathis Anastasios
Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
Conconi A, Bernasconi E, Bertoni F, Gaidano G, Cavalli F, Nassi L, Kwee I, Dirnhofer S, Scherrer A, Schmid P, Novak U, Staehelin C, Battegay M, Hasse B, Darling K, Margiotta-Casaluci G, Zucca E, Swiss HIV Cohort Study (SHCS). Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. Hematol Oncol 2018
16.08.2018Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
16.08.2018Hematol Oncol 2018
Conconi Annarita, Bernasconi Enos, Bertoni Francesco, Gaidano Gianluca, Cavalli Franco, Nassi Luca, Kwee Ivo, Dirnhofer Stephan, Scherrer Alexandra, Schmid Patrick, Novak Urban, Staehelin Cornelia, Battegay Manuel, Hasse Barbara, Darling Katharine, Margiotta-Casaluci Gloria, Zucca Emanuele, Swiss HIV Cohort Study (SHCS)
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Chigrinova E, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow S, Stilgenbauer S, Piris M, Matolcsy A, Spagnolo D, Nikitin E, Zamò A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Inghirami G, Marasca R, Rinaldi A, Kwee I, Rossi D, Rancoita P, Strefford J, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young K, Murray F, Rosenquist R, Greiner T, Chan W, Orlandi E, Lucioni M, Bertoni F. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 2013; 122:2673-82.
04.09.2013Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
04.09.2013Blood 2013; 122:2673-82
Chigrinova Ekaterina, Ladetto Marco, Forconi Francesco, Cogliatti Sergio B., Votavova Hana, Swerdlow Steven H, Stilgenbauer Stephan, Piris Miguel A, Matolcsy Andras, Spagnolo Dominic, Nikitin Eugene, Zamò Alberto, Gattei Valter, Bhagat Govind, Ott German, Zucca Emanuele, Gaidano Gianluca, Inghirami Giorgio, Marasca Roberto, Rinaldi Andrea, Kwee Ivo, Rossi Davide, Rancoita Paola M V, Strefford Jonathan C, Oscier David, Stamatopoulos Kostas, Papadaki Theodora, Berger Françoise, Young Ken H, Murray Fiona, Rosenquist Richard, Greiner Timothy C, Chan Wing C, Orlandi Ester M, Lucioni Marco, Bertoni Francesco
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma
Rinaldi A, Rossi D, Gaidano G, Zucca E, Cavalli F, Cogliatti S, Berger F, Marasca R, Gattei V, Lucioni M, Orlandi E, Forconi F, Kwee I, Mensah A, Bertoni F. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. Br J Haematol 2013; 163:194-204.
21.08.2013Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma
21.08.2013Br J Haematol 2013; 163:194-204
Rinaldi Andrea, Rossi Davide, Gaidano Gianluca, Zucca Emanuele, Cavalli Franco, Cogliatti Sergio B., Berger Françoise, Marasca Roberto, Gattei Valter, Lucioni Marco, Orlandi Ester M, Forconi Francesco, Kwee Ivo, Mensah Afua Adjeiwaa, Bertoni Francesco
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Renner C, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N, Bouabdallah K, Trojan A, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97:1085-91.
07.02.2012A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
07.02.2012Haematologica 2012; 97:1085-91
Renner Christoph, Lohri Andreas, Gyan Emmanuel, Biaggi Christine, Cogliatti Sergio B., Bertoni Francesco, Ghielmini Michele, Brauchli Peter, Ketterer Nicolas, Bouabdallah Krimo, Trojan Andreas, Zinzani Pier Luigi, Gressin Rémy, Klingbiel Dirk, Dietrich Pierre-Yves, Hitz Felicitas, Bargetzi Mario, Mingrone Walter, Martinelli Giovanni, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network
IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome
Cogliatti S, Bertoni F, Zimmermann D, Henz S, Diss T, Ghielmini M, Schmid U. IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. J Pathol 2005; 206:320-7.
01.07.2005IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome
01.07.2005J Pathol 2005; 206:320-7
Cogliatti Sergio B., Bertoni Francesco, Zimmermann Dieter R, Henz Samuel, Diss Tim C, Ghielmini Michele, Schmid Ulrico
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Bargetzi M, Ketterer N, Stahel R, Pichert G, Schefer H, Betticher D, Fey M, Waltzer U, Bertoni F, Cogliatti S, Schmitz S, Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11.
01.02.2005Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
01.02.2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11
Ghielmini Michele, Cerny Thomas, Bargetzi Mario, Ketterer Nicolas, Stahel Rolf, Pichert Gabriella, Schefer Hubert, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Bertoni Francesco, Cogliatti Sergio, Schmitz Shu-Fang Hsu, Swiss Group for Clinical Cancer Research
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
Bertoni F, Cotter F, Cavalli F, Zucca E, Auer R, Jones C, Baldini L, Ponzoni M, Bertolini F, Pichert G, Fey M, Cerny T, Ghielmini M, Schmitz S, Cogliatti S, Conconi A, Swiss Group for Clinical Cancer Research. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. British journal of haematology 2004; 124:289-98.
01.02.2004Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
01.02.2004British journal of haematology 2004; 124:289-98
Bertoni Francesco, Cotter Finbarr E, Cavalli Franco, Zucca Emanuele, Auer Rebecca, Jones Chris, Baldini Luca, Ponzoni Maurilio, Bertolini Francesco, Pichert Gabriella, Fey Martin, Cerny Thomas, Ghielmini Michele, Schmitz Shu-Fang Hsu, Cogliatti Sergio B, Conconi Annarita, Swiss Group for Clinical Cancer Research